Keith Rubin, M.D. serves on the ILiAD Executive Board and is Founder and CEO of ILiAD Biotechnologies. Prior to ILiAD, Dr. Rubin founded Seedlings Life Science Ventures, a medical technology company that has successfully developed and advanced multiple patented technologies including the out-license of IP for a commercialized auto-injector to treat anaphylaxis and FDA clearance of a device for use during prostate cancer radiotherapy. From 1990 to 2000, Dr. Rubin practiced Internal Medicine with a primary focus on the care of patients with HIV and AIDS in New York City and served as Teaching Attending at Beth Israel and Cabrini Medical Centers and St. Vincent’s Hospital. In 2000, Dr. Rubin transitioned from clinical practice to research and medical product development and his practice was acquired by St. Vincent’s Hospital. Dr. Rubin has previously served as a consultant to various pharmaceutical companies and investment firms, and has held several positions in technology innovation at the University of Miami Miller School of Medicine, including Executive Director of BioScience Ventures. He is a graduate of the University of Miami School of Medicine and holds a B.A. in Biology from Princeton University.